SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over
Status:
Completed
Trial end date:
2017-07-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to identify the effects that ageing may have on the drug levels,
the safety and the efficacy of Dolutegravir.
These effects will be measured in people who are aged 60 or over and taking antiretroviral
therapy for HIV infection.
Dolutegravir is a newly licenced anti HIV medication, which belongs to a class of drugs
called Integrase Inhibitors. It is taken with two other wellknown agents, Abacavir and
Lamivudine, as part of a one tablet once a day regimen, called Triumeq. There is little data
available on Dolutegravir in the context of older age. The HIV population is ageing and the
investigators know that older age can significantly change the effects and side effects of
medications, including that of antiretrovirals.
The investigators aim to investigate the treatment outcomes in older people taking
Dolutegravir including the tolerability, efficacy and safety of the drug.
The study will also assess the quality of life (wellbeing of individuals) and cognition
(mental abilities) of people aged 60 or over, taking Dolutegravir. The results from this
study may inform treatment choices and monitoring in this population in the future.
The duration of involvement in the study will be 6 months with an additional screening visit
and a checkup visit 10 days after end of study visit.